AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 282 min read$BDX

Feld Michael sold $12K of BDX

Feld Michael (EVP, Chief Revenue Officer) sold 75 shares of BECTON DICKINSON & CO (BDX) at $157.13 on 2026-07-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Feld Michael
Published Jul 28, 2026, 3:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 3:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BDX
Neutral
high confidence
Mentioned
$BDX
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BDXNeutralLow
01

Why it matters

The disclosed sale is pre-arranged under Rule 10b5-1, which typically limits the informational content for traders.

02

Market read

Traders may note the insider sale for sentiment monitoring, but it is unlikely to change valuation or near-term expectations.

03

What to watch

10b5-1 plans reduce interpretability; the article does not provide any new operational or financial information about BDX.

Relevance 2/10Novelty 2/10Timing: today’s SEC Form 4 filing (filed 2026-07-28)

Background

The article is an SEC Form 4 insider transaction disclosure for Becton Dickinson & Co.

Company-level read

Ticker impact

$BDXNeutralHigh confidence
Context

Becton Dickinson insider Feld Michael sold 75 shares at $157.13 on 2026-07-27 under a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal price impact; any reaction should be small and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, and the disclosed sale size is modest relative to a large-cap issuer.

Market effects

Sector

No direct sector read-through; this is company-specific insider trading disclosure.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification or tax planning, so the market may overreact to the headline optics.

Key entities

  • issuer
    Becton Dickinson & Co

    BDX, subject of the Form 4 insider transaction disclosure.

  • insider
    Feld Michael

    EVP, Chief Revenue Officer who executed the open-market sale.

Read at source← All news

Related articles

AUG 8
$REPLMed

This Week at FDA: Inspection reorg, acting CBER chief eyes IND reforms, and more

FDA updates cover inspection reorganization plans, proposed IND reforms for early-stage biologics research, and accelerated approval of Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) with Bristol Myers Squibb’s Opdivo for melanoma after PD-1 regimens. Other items include FDA workshops, Seegene EUA for an assay, and multiple drug/device recalls.

raps.org7 min
AUG 6
$BDXMed

Becton, Dickinson Boosts FY26 Adj. EPS Outlook - Update

Becton, Dickinson and Co. (BDX) reported third-quarter results and raised its FY2026 adjusted EPS outlook to $12.62 to $12.72 per share, from $12.52 to $12.72. The company kept its revenue growth view, expecting low single-digit plus growth and low single-digit constant-currency growth. Shares were about $172.00 premarket.

rttnews.com2 min
AUG 6
$BDXMedAI 8/10

BD Reports Third Quarter Fiscal 2026 Financial Results

BD (NYSE:BDX) reported fiscal 2026 third-quarter results ended June 30, 2026. Revenue rose to $5.0 billion, up 5.4% reported and 4.4% on an FX-neutral basis. GAAP and adjusted diluted EPS from continuing operations were $1.64 and $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion, and free cash flow rose 44.6% to $1.7 billion. BD updated full-year guidance, expecting revenue growth toward the high end and raised the adjusted EPS midpoint.

prnewswire.com6 min